NM_000251.3:c.1277-2A>T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.1277-2A>T variant causes a splice acceptor, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000251.3 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1445090Hom.: 0 Cov.: 27 AF XY: 0.00 AC XY: 0AN XY: 720134
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Lynch syndrome Pathogenic:1
MSH2 NM_000251.2:c.1277-2A>T has a 98.1% probability of pathogenicity based on combining prior probability from public data with a likelihood ratio of 1.56 to 1, generated from evidence of seeing this as a somatic mutation in a tumor without loss of heterozygosity at the MSH2 locus. See Shirts et al 2018, PMID 29887214. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1277-2A>T intronic pathogenic mutation results from an A to T substitution two nucleotides upstream from coding exon 8 in the MSH2 gene. Using a Bayesian analysis that incorporates tumor mutation data, this variant was classified as likely pathogenic (Shirts BH et al. Am J Hum Genet, 2018 07;103:19-29). Two alterations impacting the same acceptor site (c.1277-2A>G and c.1277-1G>A) have been detected in individuals meeting either Amsterdam criteria or Bethesda guidelines for hereditary non-polyposis colorectal cancer (HNPCC)/Lynch syndrome and had colorectal tumors displaying high microsatellite instability with loss of MSH2 protein staining on immunohistochemistry (Sheng JQ et al. Chin J Dig Dis, 2006;7:197-205; Goldberg Y et al. Fam. Cancer, 2008 Apr;7:309-17; Sjursen W et al. J. Med. Genet., 2010 Sep;47:579-85; Tian W et al. Int J Cancer. 2019 Sep 1;145(5):1290-1298). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at